FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892095332> ?p ?o ?g. }

• W2892095332 endingPage "8506" @default.
• W2892095332 startingPage "8506" @default.
• W2892095332 abstract "8506 Background: The antitumor activity of pembrolizumab, an IgG4 anti-PD-1 monoclonal antibody, was evaluated in patients (pts) with SCLC in KEYNOTE-158 (NCT02628067), a phase 2 basket study of 11 cancer types. Methods: Enrolled pts were aged ≥18 y with advanced SCLC; had measurable disease per RECIST v1.1; ECOG PS ≤1; incurable disease with prior failure of, progression on, or intolerance to standard therapy; and evaluable tumor samples for PD-L1 (PD-L1 IHC 22C3 pharmDx assay [Agilent Technologies]) and other biomarkers. Pembrolizumab 200 mg Q3W was administered for 2 y or until disease progression or intolerable toxicity. The primary endpoint was ORR. DOR, PFS, and OS were secondary endpoints and were estimated by the Kaplan-Meier method. Tumor imaging was performed every 9 wks for the first year, then every 12 wks. Response was assessed per RECIST v1.1 by independent central radiologic review. PD-L1–positive was defined as PD-L1 combined positive score ≥1. Results: Among 107 SCLC pts, median age was 63 y (range, 24–84) and 85 (79%) had 1–2 prior therapies. At the data cutoff date (Aug 23, 2017), 36 pts (34%) were continuing on-study; median follow-up was 10.1 mo (range, 0.5–17.5). Tumors were PD-L1–positive in 42 pts (39%) and PD-L1–negative in 50 (47%); 0 had microsatellite instability-high (MSI-H) tumors and 83 (78%) had microsatellite-stable (MSS) tumors. ORR was 18.7% (20/107; 95% CI, 11.8–27.4) overall, 35.7% (15/42; 95% CI, 21.6–52.0) in pts with PD-L1–positive tumors, and 6.0% (3/50; 95% CI, 1.3–16.5) in pts with PD-L1–negative tumors. Overall, median DOR had not been reached (range, 2.1+ to 13.2+ mo); 12 pts (77%) had DOR ≥9 mo. Median PFS was 2.0 mo (95% CI, 1.9–2.1) in all pts, 2.1 mo (95% CI, 2.0–9.9) in pts with PD-L1–positive tumors, and 1.9 mo (95% CI, 1.6–2.0) in pts with PD-L1–negative tumors. Median OS was 9.1 mo (95% CI, 5.7–14.6) overall, 14.6 mo (5.6–not estimable) in pts with PD-L1–positive tumors, and 7.7 mo (95% CI, 3.9–10.4) in pts with PD-L1–negative tumors. Treatment-related AEs occurred in 63 pts (59%) and led to 4 discontinuations and 1 death (pneumonia). Conclusions: Pembrolizumab has shown promising antitumor activity and durable responses in advanced SCLC, especially in pts with PD-L1–positive tumors. Clinical trial information: NCT02628067." @default.
• W2892095332 created "2018-09-27" @default.
• W2892095332 creator A5002480807 @default.
• W2892095332 creator A5014113942 @default.
• W2892095332 creator A5016994371 @default.
• W2892095332 creator A5020672869 @default.
• W2892095332 creator A5026538331 @default.
• W2892095332 creator A5028020706 @default.
• W2892095332 creator A5039952118 @default.
• W2892095332 creator A5048013287 @default.
• W2892095332 creator A5052759717 @default.
• W2892095332 creator A5062297013 @default.
• W2892095332 creator A5065124595 @default.
• W2892095332 creator A5065206480 @default.
• W2892095332 creator A5071577235 @default.
• W2892095332 creator A5080626646 @default.
• W2892095332 creator A5084710985 @default.
• W2892095332 creator A5090832721 @default.
• W2892095332 date "2018-05-20" @default.
• W2892095332 modified "2023-10-17" @default.
• W2892095332 title "Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158." @default.
• W2892095332 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.8506" @default.
• W2892095332 hasPublicationYear "2018" @default.
• W2892095332 type Work @default.
• W2892095332 sameAs 2892095332 @default.
• W2892095332 citedByCount "123" @default.
• W2892095332 countsByYear W28920953322018 @default.
• W2892095332 countsByYear W28920953322019 @default.
• W2892095332 countsByYear W28920953322020 @default.
• W2892095332 countsByYear W28920953322021 @default.
• W2892095332 countsByYear W28920953322022 @default.
• W2892095332 countsByYear W28920953322023 @default.
• W2892095332 crossrefType "journal-article" @default.
• W2892095332 hasAuthorship W2892095332A5002480807 @default.
• W2892095332 hasAuthorship W2892095332A5014113942 @default.
• W2892095332 hasAuthorship W2892095332A5016994371 @default.
• W2892095332 hasAuthorship W2892095332A5020672869 @default.
• W2892095332 hasAuthorship W2892095332A5026538331 @default.
• W2892095332 hasAuthorship W2892095332A5028020706 @default.
• W2892095332 hasAuthorship W2892095332A5039952118 @default.
• W2892095332 hasAuthorship W2892095332A5048013287 @default.
• W2892095332 hasAuthorship W2892095332A5052759717 @default.
• W2892095332 hasAuthorship W2892095332A5062297013 @default.
• W2892095332 hasAuthorship W2892095332A5065124595 @default.
• W2892095332 hasAuthorship W2892095332A5065206480 @default.
• W2892095332 hasAuthorship W2892095332A5071577235 @default.
• W2892095332 hasAuthorship W2892095332A5080626646 @default.
• W2892095332 hasAuthorship W2892095332A5084710985 @default.
• W2892095332 hasAuthorship W2892095332A5090832721 @default.
• W2892095332 hasConcept C121608353 @default.
• W2892095332 hasConcept C126322002 @default.
• W2892095332 hasConcept C143998085 @default.
• W2892095332 hasConcept C203092338 @default.
• W2892095332 hasConcept C2776256026 @default.
• W2892095332 hasConcept C2777701055 @default.
• W2892095332 hasConcept C2779984678 @default.
• W2892095332 hasConcept C2780057760 @default.
• W2892095332 hasConcept C31760486 @default.
• W2892095332 hasConcept C535046627 @default.
• W2892095332 hasConcept C71924100 @default.
• W2892095332 hasConcept C90924648 @default.
• W2892095332 hasConceptScore W2892095332C121608353 @default.
• W2892095332 hasConceptScore W2892095332C126322002 @default.
• W2892095332 hasConceptScore W2892095332C143998085 @default.
• W2892095332 hasConceptScore W2892095332C203092338 @default.
• W2892095332 hasConceptScore W2892095332C2776256026 @default.
• W2892095332 hasConceptScore W2892095332C2777701055 @default.
• W2892095332 hasConceptScore W2892095332C2779984678 @default.
• W2892095332 hasConceptScore W2892095332C2780057760 @default.
• W2892095332 hasConceptScore W2892095332C31760486 @default.
• W2892095332 hasConceptScore W2892095332C535046627 @default.
• W2892095332 hasConceptScore W2892095332C71924100 @default.
• W2892095332 hasConceptScore W2892095332C90924648 @default.
• W2892095332 hasIssue "15_suppl" @default.
• W2892095332 hasLocation W28920953321 @default.
• W2892095332 hasOpenAccess W2892095332 @default.
• W2892095332 hasPrimaryLocation W28920953321 @default.
• W2892095332 hasRelatedWork W2406666623 @default.
• W2892095332 hasRelatedWork W2890639244 @default.
• W2892095332 hasRelatedWork W2947556250 @default.
• W2892095332 hasRelatedWork W3135426710 @default.
• W2892095332 hasRelatedWork W3177224496 @default.
• W2892095332 hasRelatedWork W3213977202 @default.
• W2892095332 hasRelatedWork W4226256362 @default.
• W2892095332 hasRelatedWork W4282958947 @default.
• W2892095332 hasRelatedWork W4322775203 @default.
• W2892095332 hasRelatedWork W4361947625 @default.
• W2892095332 hasVolume "36" @default.
• W2892095332 isParatext "false" @default.
• W2892095332 isRetracted "false" @default.
• W2892095332 magId "2892095332" @default.
• W2892095332 workType "article" @default.